Q2 revenue $8.5M, net loss $5.1M; arimoclomol NDA resubmission on track for Q4 2023

ZEVRA THERAPEUTICS, INC.

Net revenue $8.5M in Q2 2023 vs $1.3M YoY, driven by $5M AZSTARYS milestone and royalties.
Net loss $5.1M ($0.15/share) vs $24.0M ($0.70) in Q2 2022; prior year included $17.7M acquired IPR&D charge.
Cash $87.4M as of June 30, 2023, supporting operations into 2026; $5M milestone received after quarter-end.
Pre-submission meeting with FDA for arimoclomol NDA completed; resubmission expected Q4 2023.
Phase 2 KP1077 IH trial enrolling; interim data expected Q3 2023; topline data H1 2024; narcolepsy IND opened.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ZEVRA THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: revenue $8.5 million, net income ($5.1) million, EPS ($0.15).

Period: second quarter ended June 30, 2023
Revenue: $8.5 million
Net income: ($5.1) million
EPS: ($0.15)
Result: reported results

Exact text from the filing

Net revenue for Q2 2023 was $8.5 million compared to Q2 2022 net revenue of $1.3 million.

View on SEC.gov

Browse all earnings releases →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-023412

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.